These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 26578234)

  • 41. High phosphoantigen levels in bisphosphonate-treated human breast tumors promote Vgamma9Vdelta2 T-cell chemotaxis and cytotoxicity in vivo.
    Benzaïd I; Mönkkönen H; Stresing V; Bonnelye E; Green J; Mönkkönen J; Touraine JL; Clézardin P
    Cancer Res; 2011 Jul; 71(13):4562-72. PubMed ID: 21646473
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Dosing related effects of zoledronic acid on bone markers and creatinine clearance in patients with multiple myeloma and metastatic breast cancer.
    Søe K; Delaissé JM; Jakobsen EH; Hansen CT; Plesner T
    Acta Oncol; 2014 Apr; 53(4):547-56. PubMed ID: 24164102
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Visualizing mineral binding and uptake of bisphosphonate by osteoclasts and non-resorbing cells.
    Coxon FP; Thompson K; Roelofs AJ; Ebetino FH; Rogers MJ
    Bone; 2008 May; 42(5):848-60. PubMed ID: 18325866
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Zoledronic acid protects against osteosarcoma-induced bone destruction but lacks efficacy against pulmonary metastases in a syngeneic rat model.
    Labrinidis A; Hay S; Liapis V; Findlay DM; Evdokiou A
    Int J Cancer; 2010 Jul; 127(2):345-54. PubMed ID: 19924813
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bone-Bound Bisphosphonates Inhibit Proliferation of Breast Cancer Cells.
    Park YE; Bava U; Lin JM; Cornish J; Naot D; Reid IR
    Calcif Tissue Int; 2019 Nov; 105(5):497-505. PubMed ID: 31324954
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bisphosphonate-induced ATP analog formation and its effect on inhibition of cancer cell growth.
    Mönkkönen H; Kuokkanen J; Holen I; Evans A; Lefley DV; Jauhiainen M; Auriola S; Mönkkönen J
    Anticancer Drugs; 2008 Apr; 19(4):391-9. PubMed ID: 18454049
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cancer experimental bone metastasis in mouse models.
    Toneri M; Miwa S; Zhang Y; Hu C; Yano S; Matsumoto Y; Bouvet M; Nakanishi H; Hoffman RM; Zhao M
    Oncotarget; 2015 Oct; 6(31):31335-43. PubMed ID: 26431498
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.
    Salzano G; Marra M; Porru M; Zappavigna S; Abbruzzese A; La Rotonda MI; Leonetti C; Caraglia M; De Rosa G
    Int J Pharm; 2011 Jan; 403(1-2):292-7. PubMed ID: 21055454
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bone-Seeking Matrix Metalloproteinase-2 Inhibitors Prevent Bone Metastatic Breast Cancer Growth.
    Tauro M; Shay G; Sansil SS; Laghezza A; Tortorella P; Neuger AM; Soliman H; Lynch CC
    Mol Cancer Ther; 2017 Mar; 16(3):494-505. PubMed ID: 28069877
    [TBL] [Abstract][Full Text] [Related]  

  • 50. How do bisphosphonates inhibit bone metastasis in vivo?
    Fournier PG; Stresing V; Ebetino FH; Clézardin P
    Neoplasia; 2010 Jul; 12(7):571-8. PubMed ID: 20651986
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Trastuzumab enhanced the cytotoxicity of Vγ9Vδ2 T cells against zoledronate-sensitized osteosarcoma cells.
    Liu M; Sun LL; Li YJ; Li HY; Zhang J; Li BH; Ye ZM
    Int Immunopharmacol; 2015 Sep; 28(1):160-7. PubMed ID: 26071219
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases.
    Ibrahim A; Scher N; Williams G; Sridhara R; Li N; Chen G; Leighton J; Booth B; Gobburu JV; Rahman A; Hsieh Y; Wood R; Vause D; Pazdur R
    Clin Cancer Res; 2003 Jul; 9(7):2394-9. PubMed ID: 12855610
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of matrix macromolecules and functional properties of breast cancer cells are modulated by the bisphosphonate zoledronic acid.
    Dedes PG; Gialeli Ch; Tsonis AI; Kanakis I; Theocharis AD; Kletsas D; Tzanakakis GN; Karamanos NK
    Biochim Biophys Acta; 2012 Dec; 1820(12):1926-39. PubMed ID: 22884656
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Bisphosphonates and their impact on disseminated tumor cells in early stage breast cancer.
    Li J; Rugo HS
    Breast Dis; 2011; 33(2):83-92. PubMed ID: 22142661
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Effect of zoledronate acid treatment on osseointegration and fixation of implants in autologous iliac bone grafts in ovariectomized rabbits.
    Qi M; Hu J; Li J; Li J; Dong W; Feng X; Yu J
    Bone; 2012 Jan; 50(1):119-27. PubMed ID: 22023930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bone metastasis targeting: a novel approach to reach bone using Zoledronate anchored PLGA nanoparticle as carrier system loaded with Docetaxel.
    Ramanlal Chaudhari K; Kumar A; Megraj Khandelwal VK; Ukawala M; Manjappa AS; Mishra AK; Monkkonen J; Ramachandra Murthy RS
    J Control Release; 2012 Mar; 158(3):470-8. PubMed ID: 22146683
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
    Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
    J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Use of zoledronate to treat osteoblastic versus osteolytic lesions in a severe-combined-immunodeficient mouse model.
    Lee YP; Schwarz EM; Davies M; Jo M; Gates J; Zhang X; Wu J; Lieberman JR
    Cancer Res; 2002 Oct; 62(19):5564-70. PubMed ID: 12359769
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Zoledronic acid treatment impairs protein geranyl-geranylation for biological effects in prostatic cells.
    Goffinet M; Thoulouzan M; Pradines A; Lajoie-Mazenc I; Weinbaum C; Faye JC; Séronie-Vivien S
    BMC Cancer; 2006 Mar; 6():60. PubMed ID: 16539721
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
    Hiraga T; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.